Home Cart 0 Sign in  

[ CAS No. 35661-60-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 35661-60-0
Chemical Structure| 35661-60-0
Structure of 35661-60-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 35661-60-0 ]

Related Doc. of [ 35661-60-0 ]

Alternatived Products of [ 35661-60-0 ]
Product Citations

Product Citations

Agrawal, Anushka ; Euliano, Erin M ; Pogostin, Brett H , et al. DOI:

Abstract: Introduction Multidomain peptides (MDPs) are amino acid sequences that self-assemble to form supramolecular hydrogels under physiological conditions that have shown promise for a number of biomedical applications. K2(SL)6K2 (“K2”), a widely studied MDP, has demonstrated the ability to enhance the humoral immune response to co-delivered antigen. Herein, we sought to explore the in vitro and in vivo properties of a peptide with the same sequence but opposite chirality (D-K2) since peptides composed of D-amino acids are resistant to protease degradation and potentially more immunostimulatory than their canonical counterparts. Methods K2 and D-K2 hydrogels were characterized and evaluated in vitro using circular dichroism, rheology, cryo-electron microscopy, and fuorescence recovery after photobleaching studies. In vivo experiments in SKH-1 mice were conducted to evaluate both ovalbumin release from the hydrogels and hydrogel degradation. The injection site of the hydrogels was analyzed using histology and humoral immunity was assessed by ELISA. Results In vitro, the enantiomeric hydrogels exhibited similar rheological properties, and fuorescence recovery after pho_x005f_x0002_tobleaching experiments demonstrated that the difusion of ovalbumin (OVA), a model antigen, was similar within both hydrogels. In vivo, K2 and D-K2 peptide hydrogels had similar OVA release rates, both releasing 89% of the antigen within 8 days. Both hydrogels elicited a similar antigen-specifc humoral immune response. However, the in vivo degradation of the D-K2 hydrogel progressed signifcantly slower than K2. After 4 weeks in vivo, only 23±7% of the K2 hydrogel remained at the injection site compared to 94±7% of the D-K2 hydrogel, likely due to their diferent protease susceptibilities. Conclusion Taken together, these data suggest that peptide chirality can be a useful tool for increasing hydrogel residence time for biomedical applications that would beneft from long persistence times and that, if an antigen releases over a suf_x005f_x0002_fciently short period, release can be largely independent of degradation rate, though slower-difusing payloads may exhibit degradation rate dependence.

Keywords: Hydrogel ; Chirality ; Degradation ; Drug delivery ; Peptides ; Adjuvants

Purchased from AmBeed: ; ; ; ;

Product Details of [ 35661-60-0 ]

CAS No. :35661-60-0 MDL No. :MFCD00037133
Formula : C21H23NO4 Boiling Point : -
Linear Structure Formula :OHCOCH(CH2CH(CH3)2)NHCOOCH2C13H9 InChI Key :CBPJQFCAFFNICX-IBGZPJMESA-N
M.W : 353.41 Pubchem ID :1549133
Synonyms :
Fmoc-leucine;N-FMOC-leucine;FMOC-Leu;FMOC-L-Leucine;NSC 334290;NPC 15199

Calculated chemistry of [ 35661-60-0 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 26
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.33
Num. rotatable bonds : 8
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 99.59
TPSA : 75.63 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.35 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.43
Log Po/w (XLOGP3) : 4.38
Log Po/w (WLOGP) : 4.02
Log Po/w (MLOGP) : 3.0
Log Po/w (SILICOS-IT) : 3.55
Consensus Log Po/w : 3.48

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -4.6
Solubility : 0.00879 mg/ml ; 0.0000249 mol/l
Class : Moderately soluble
Log S (Ali) : -5.68
Solubility : 0.000731 mg/ml ; 0.00000207 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.71
Solubility : 0.000689 mg/ml ; 0.00000195 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 3.0
Synthetic accessibility : 3.86

Safety of [ 35661-60-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 35661-60-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 35661-60-0 ]

[ 35661-60-0 ] Synthesis Path-Downstream   1~14

  • 1
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C35H60N8O7 [ No CAS ]
  • 2
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C41H71N9O8 [ No CAS ]
  • 3
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C23H38N6O5 [ No CAS ]
  • C46H76N12O10 [ No CAS ]
  • 4
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C29H49N7O6 [ No CAS ]
  • C58H98N14O12 [ No CAS ]
  • 5
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C35H60N8O7 [ No CAS ]
  • C70H120N16O14 [ No CAS ]
  • 6
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C41H71N9O8 [ No CAS ]
  • 7
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C34H54N10O8 [ No CAS ]
  • 8
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C17H27N5O4 [ No CAS ]
  • 9
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C23H38N6O5 [ No CAS ]
  • 10
  • [ 35661-60-0 ]
  • [ 79410-33-6 ]
  • [ 198561-07-8 ]
  • C29H49N7O6 [ No CAS ]
  • 11
  • [ 159610-89-6 ]
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-32-4 ]
  • 12
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-30-2 ]
  • 13
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-28-8 ]
  • 14
  • [ 35661-60-0 ]
  • [ 198561-07-8 ]
  • C26H28N3O4Pol [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Similar Product of
[ 35661-60-0 ]

Chemical Structure| 200937-57-1

A987274[ 200937-57-1 ]

Fmoc-Leu-OH-15N

Reason: Stable Isotope

Chemical Structure| 202114-53-2

A1269541[ 202114-53-2 ]

Fmoc-Leu-OH-1-13C

Reason: Stable Isotope

Chemical Structure| 200937-57-1

A1371553[ 200937-57-1 ]

Fmoc-Leu-OH-15N

Reason: Stable Isotope

Chemical Structure| 200937-57-1

A1371552[ 200937-57-1 ]

Fmoc-Leu-OH-15N

Reason: Stable Isotope

; ;